Research revealed that silencing the FBXW7 gene can promote the development of EMT and confer resistance to sorafenib and cisplatin in non-small cell lung cancer (NSCLC) (Xiao G. et al., 2018). This evidence concerns the gene FBXW7 and non-small cell lung carcinoma.